Categories: HealthIndonesia

The Good Advancement for the Preparation of COVID-19 for Indonesia

Indonesia has sought a report from Brazil, where a similar study is going smoothly in terms of the sluggish advancement of its own Phase 3 clinical trial of a COVID-19 vaccine candidate.

They are looking forward to collect safety and efficacy data by the end of this month on the Chinese company which is Sinovac Biotech’s CoronaVac, and hoping to finally begin carrying out its vaccination program this 2021.

Meanwhile for a government official who spoke on condition of anonymity, BPOM, the Indonesian counterpart of the US Food and Drug Administration, demanded the data through its Foreign Affairs Ministry, which then contacted Brazil’s National Health Surveillance Agency and Sinovac.

Penny K. Lukito the head of BPOM, had earlier highlighted that a vaccine can be picked as long as it has gone through the correct testing. In fact, Indonesia has received commitments for 189 million vaccine doses from Sinovac, US-based Novavax, and Covax, a World Health Organization co-led international COVID-19 vaccine allocation platform which is actually a good progress for the preparation.

Consequently, the countries expected to use CoronaVac as part of their vaccine programme are Brazil, Indonesia, Singapore and Turkey. Morever, Indonesia, the most populous country in South-East Asia, plans to vaccinate 107.2 million people between the ages of 18 and 59, out of its 270 million population. There will be no representation of people with medical problems or who are found unfit.

It has also set aside a buffer of 15 per cent for its vaccine stockpile. It is also given that the vaccine is given in two doses, by next year, 247 million doses will be required in its stockpile. Indonesia had intended to launch its vaccination campaign as early as last month, but it had to be postponed, with CoronaVac’s poorly structured Phase 3 clinical trial failing to collect the data to approve the vaccine.

For this reason, The state-run drugmaker Bio Farma and the West Java University of Padjadjaran, which began conducting the trial in August, were unable to provide an interim report, a requirement before BPOM could review the vaccine for emergency use approval. There is a smaller probability that the requisite number of participants will be exposed to pathogens, with just 1,600 volunteers in the trial and a shortage of people from risk groups – such as medical staff. At least 1.5 percent of the 1,600 volunteers must have contracted the virus so that they can be tracked to test the effectiveness of the vaccine candidate.

Noto

Jakarta-based Newswriter for The Asian Affairs. A budding newswriter that always keep track of the latest trends and news that are happening in my country Indonesia.

Recent Posts

Bangchak Reduces the Price of Premium Oil to 5 baht Ahead of Christmas & New Year

BCP (Bangchak Corporation Petroleum Public Company Limited) has announced a New Year gift to the users of BCP Premium oil…

December 23, 2024

Vietnam International Defense Expo 2024

The 2024 Vietnam International Defense Expo was inaugurated by the Prime Minister Pham Minh Chinh on December 19, 2024 and…

December 22, 2024

Shooting concludes: Stranger Things 5 to release on Netflix in 2025

Created by the Duffer Brothers, Stranger Things is one of the most popular sci-fi horror series globally. It is set…

December 21, 2024

China’s Hypersonic Expansion in Asia Raises Alarms for India

According to the US Department of Defense, China has now produced the most sophisticated supply of hypersonic weapons in the…

December 21, 2024

Melaka International Halal Festival 2024

The Melaka International Halal Festival 2024 aims to turn the city as the prime center of the Halal products and…

December 21, 2024

Chunichi Dragons Renews the Contract of Hiroto Takahashi with Annual Salary of 120 million yen

On Saturday, the stalwart of Chunichi Dragons Pitcher, Hiroto Takahashi attended the negotiation for his contract renewal for the next…

December 21, 2024

This website uses cookies.

Read More